Tag: IMM
Immutep receives US patent for the use of LAG525 antibody in treating various cancers
Biotech company Immutep (ASX: IMM) has been granted a US patent directed to embodiments of LAG525, a humanised form of its IMP701 antibody.
The patent is directed to nucleic acid molecules which co...
Immutep publishes interim results for two ongoing studies, scoops $3.6 million in R&D grant
Biotechnology company Immutep (ASX: IMM) has published results from two ongoing clinical studies, just days after revealing it received €2.1 million (A$3.6 million) in research and development tax inc...
Immutep receives further FDA approval for efti cancer drug
Biotechnology company Immutep (ASX: IMM) has received approval from the US Food and Drug Administration for an investigational new drug (IND) application relating to its lead product candidate eftilag...
Immutep reports positive data from ongoing trial into cancer drug efti
Biotechnology company Immutep (ASX: IMM) is set to unveil interim data from its ongoing phase 2 TACTI-002 study into its efti drug at the 34th German Cancer Congress in Berlin, Germany taking place to...
Immutep expands clinical trial for lead drug candidate efti
Biotech company Immutep (ASX: IMM) intends to expand ongoing development of its lead drug candidate eftilagimod alpha, otherwise known as “efti”, after welcoming positive clinical data from its TACTI-...
Positive safety data reported from Immutep’s clinical trial to treat metastatic melanoma
Biotechnology company Immutep (ASX: IMM) has reported “mature positive efficacy data” from a phase I clinical study combining lead drug candidate eftilagimod alpha with Keytruda in the treatment of me...
Immutep recruits more patients for non-small cell lung cancer trial, banks milestone payment from GlaxoSmithKline
Sydney-based biotechnology company Immutep (ASX: IMM) has reported a successful roll-out to part A of its TACTI-002 phase II clinical trial for patients with previously-untreated, inoperable or metast...
Immutep signs agreements with Japanese biotech to develop therapeutic cancer vaccine
Australian biotechnology company Immutep (ASX: IMM) has entered into three agreements with Japanese cancer vaccine development company Cytlimic Inc for its lead product candidate eftilagimod alpha.
...
Immutep delivers flurry of developments for lead cancer drug candidate ‘eftilagimod alpha’
Biotechnology company Immutep (ASX: IMM) has brought out a flurry of developments over the past few days including new data from its ongoing TACTI-mel Phase 1 clinical trial as well as two distinct ne...
Immutep on track to develop novel solution to cancer and autoimmune diseases
Dual-listed biotechnology company Immutep (ASX: IMM) has published new data from its ongoing TACTI-mel phase 1 clinical trial and presented its findings at the 33rd annual meeting of the Society for I...
Immutep joins forces with Merck and Pfizer to advance immunotherapy treatment
Biotechnology company Immutep (ASX: IMM) has announced a trial collaboration and supply agreement with Merck KGaA and Pfizer Inc.
The agreement allows the emergent biotech company to evaluate a com...
Immutep recruits final patient for melanoma trial, receives Canadian patent for antibody
Australian biotech developer Immutep (ASX: IMM) has provided an update on the ongoing clinical development of its immunotherapy product efti, as well as its partnered clinical programs.
The company...
Immutep broadcasts encouraging progress of its clinical trial
Biotech developer Immutep (ASX: IMM) unveiled new data in a public webcast regarding its ongoing melanoma study. The Australian biotech company said that it has achieved long-lasting and durable respo...
Merck and Immutep to collaborate on novel clinical trial
US pharma giant Merck & Co, is maintaining it proactive Australian streak, by announcing a collaborative deal with Australian biotech company Immutep (ASX: IMM), as part of clinical trials of thei...
